$GNPX News

Genprex Showcases Positive Preclinical Data On Its Diabetes Gene Therapy Drug Candidate At 2026 American Society Of Gene And Cell Therapy Annual Meeting

Genprex Q1 EPS $(0.64) Up From $(13.00) YoY

Israel Patent Office Grants Genprex Patent Covering Use Of Reqorsa Gene Therapy In Combination With PD-1 Antibodies For Treatment Of Cancer

Genprex Signs Research Agreement With MD Anderson To Study Biomarkers Predicting Response To Reqorsa Gene Therapy In Lung Cancer Trials

Genprex Signs Research Agreement With MD Anderson To Study Biomarkers Predicting Response To Reqorsa Gene Therapy In Lung Cancer Trials

Genprex Research Collaborators Presents Preclinical Data From Studies Of Lead Drug Candidate, Reqorsa Gene Therapy For Treatment Of Lung Cancer At 2026 AACR Annual Meeting

Genprex Collaborators To Present Positive Preclinical REQORSA Gene Therapy Lung Cancer Data At AACR 2026

Genprex shares are trading higher after the company announced that the Japanese Patent Office has issued a favorable Appeal Decision to grant a patent claiming the use of Reqorsa Gene Therapy in combination with PD-L1 antibodies to treat cancer.

Genprex Says Japanese Patent Office Issues Favourable Appeal Decision To Grant Patent Claiming Use Of Reqorsa Gene Therapy In Combination With PD-L1 Antibodies To Treat Cancer

Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers

Congressman Who Was Top 2025 Stock Picker Buys Shares Of $5M Company You've Never Heard Of

Genprex Provides Clinical Update on Diabetes Gene Therapy Program

Genprex Announces Clinical Program Update On GPX-002 Diabetes Gene Therapy Candidate

Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Genprex Announces Preliminary in Vivo Preclinical Proof-of-concept Data for GPX-002 Diabetes Gene Therapy Drug Candidate, in a Non-human Primate Model and Mouse Model of Type 2 Diabetes

Move Over, Pelosi: This Congress Member Posted 2025's Best Market Return With A 52% Gain

Congressman Buys Shares Of Small Cap Lift Truck Company You've Probably Never Heard Of

Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer

Genprex Reports Early Success For Its New Gene Therapy In Advanced Lung Cancer Trial